Takara Bio Inc는 주당 17.0078의 연간 배당금을 지급하며, 수익률은 0.00%입니다. 배당금은 반기별에 지급되며, 마지막 배당금 지급일은 Mar 28, 2025였습니다.
배당수익률
연간 배당금
배당금 지급일 전일
0.00%
$17.0078
Mar 28, 2025
지급 빈도
지급 비율
반기별
0.00%
배당금 이력
배당금 지급일 전일
현금 금액
기록 일자
지급일
Mar 28, 2025
$17.00
Mar 31, 2025
Jun 25, 2025
Mar 28, 2024
$17.00
Mar 31, 2024
Jun 24, 2024
Mar 30, 2023
$42.00
Mar 31, 2023
Jun 26, 2023
Mar 30, 2022
$33.00
Mar 31, 2022
Jun 27, 2022
Mar 30, 2021
$16.00
Mar 31, 2021
Jun 25, 2021
Mar 30, 2020
$8.00
Mar 31, 2020
Jun 24, 2020
배당금 차트
TKBIF 배당금
TKBIF 배당금 성장률(년간 비교)
Follow-Up Questions
Takara Bio Inc의 현재 배당금과 연간 배당금은 얼마인가요?
Takara Bio Inc의 배당 성향은 얼마인가요?
TKBIF의 배당락일은 언제인가요?
Takara Bio Inc은 얼마나 자주 배당금을 지급하나요?
주요 통계
이전 종가
$5
시가
$23.2
일일 범위
$5 - $23.2
52주 범위
$5 - $23.2
거래량
20
평균 거래량
290
EPS(TTM)
--
배당수익률
--
시가총액
$602.1M
TKBIF란 무엇인가요?
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm has one business segment. The reagents, instruments and contract services business provides biotechnology-related research reagents, laboratory instruments and contract services to universities, research institutions and corporations, offering products in the fields of molecular and cell biology based on technologies including polymerase chain reaction (PCR), next-generation sequencing, genome editing and stem cells. The firm also promotes its contract development and manufacturing organization (CDMO) business, which includes contract manufacturing of regenerative medicine products and genetic analysis services. The gene therapy business advances the development of gene therapy drugs including genetically modified T-cell therapies and next-generation chimeric antigen receptor (CAR) technologies.